Compare Adaptive Biotechnologies Corp (ADPT) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs PubMatic Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while PubMatic Inc trades at $17.22 (market cap $804.41M). The key difference: Adaptive Biotechnologies Corp is far larger — about 5× PubMatic Inc's market cap. Which is the better fit depends on your goals.
| ADPT | PUBM | |
|---|---|---|
Market Cap | $4.04B | $804.41M |
Sector | Health | Technology |
52-Week High | $25.45 | $17.78 |
52-Week Low | $12.30 | $6.28 |
Enterprise Value | $4.10B | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
PubMatic trades at $17.39, down 2.08% today, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue reached $282.93M in 2025, though net income was negative. Recent Q2 2026 earnings beat expectations with 10.5% revenue growth, and the company appointed a new Chief Revenue Officer to drive AI-advertising growth.
The stock offers upside to the $20.83 consensus price target, supported by analyst buy ratings and operational cash flow strength. Risks include persistent unprofitability, high P/E ratio, and CFO transition. Positive sentiment from recent earnings beats and strategic hires suggests potential for recovery if margin improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
